Clinical Trials
9 trialsNCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00074308 2018-06-20
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00387751 2017-11-22
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00397982 2017-06-09
Mel47
National Cancer Institute (NCI)
Phase 2 Completed
NCT00026221 2016-03-17
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00538005 2014-01-10
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00255762 2013-10-28
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01217398 2013-08-26
Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00734890 2012-03-16
Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Completed